Explore the full record of transactions filed by Celine Roger-Dalbert, Directrice exécutive Recherche et Développement (Executive Vice President, R&D) chez bioMérieux. Director active across 1 companies, notably BIOMERIEUX. Aggregated, 1 disclosures have been published. The latest transaction was filed on 7 July 2025 — Souscription. Regulator: AMF. All data is openly available.
1 of 1 declaration
Céline Roger-Dalbert is a French healthcare executive with a strong background in in vitro diagnostics, research and development, microbiology, and regulated innovation. Since March 1, 2024, she has served as Executive Vice President, Research & Development at bioMérieux and sits on the company’s Executive Committee. In this role, she is responsible for leading the group’s R&D strategy, a core driver of value for a global leader in diagnostics serving healthcare professionals worldwide. Before taking on this executive position, she joined bioMérieux in August 2022 as Senior Vice President of R&D for Clinical Operations and Regulatory Affairs. In that position, she worked at the intersection of research, clinical development, and regulatory execution, helping ensure that innovation programs were aligned with product validation and market access requirements. Her experience is especially relevant in diagnostics, where scientific performance must be matched by rigorous compliance and effective industrialization. Roger-Dalbert began her career at bioMérieux in various microbiology R&D management roles, building deep technical knowledge of diagnostic technologies, culture media, and laboratory needs. She later spent around 15 years at Becton Dickinson, where she held leadership positions in R&D and program management across molecular diagnostics, microbiology, and point-of-care diagnostics, with responsibilities in Canada and the United States. She holds a master’s degree in biotechnology from the Université Catholique de Lyon. Her profile combines scientific credibility, operational discipline, and the ability to lead international innovation portfolios. Her key strengths include leading multidisciplinary teams, structuring applied research programs, and turning scientific advances into practical diagnostic solutions. She has also contributed to peer-reviewed scientific publications, reinforcing her standing within the applied microbiology community.